Biomarkers, surrogate end points, and the accelleration of drug development for cancer prevention and treatment: An update

Gary J. Kelloff, Robert C. Bast, Donald S. Coffey, Anthony V. D'Amico, Robert S. Kerbel, John W. Park, Raymond W. Ruddon, Gordon J.S. Rustin, Richard L. Schilsky, Caroline C. Sigman, George F. Vande Woude

Research output: Contribution to journalReview article

Original languageEnglish (US)
Pages (from-to)3881-3884
Number of pages4
JournalClinical Cancer Research
Volume10
Issue number11
DOIs
StatePublished - Jun 1 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kelloff, G. J., Bast, R. C., Coffey, D. S., D'Amico, A. V., Kerbel, R. S., Park, J. W., Ruddon, R. W., Rustin, G. J. S., Schilsky, R. L., Sigman, C. C., & Vande Woude, G. F. (2004). Biomarkers, surrogate end points, and the accelleration of drug development for cancer prevention and treatment: An update. Clinical Cancer Research, 10(11), 3881-3884. https://doi.org/10.1158/1078-0432.CCR-03-0783